Challenges for structure-based HIV vaccine design

Purpose of reviewWe review structural information on the native HIV envelope trimer and the known epitopes for broadly neutralizing antibodies and discuss how this structural information should guide the design of more effective immunogens. Recent findingsRecent epitope mapping of HIV-positive sera demonstrates that the immune system is able to mount a potent and broadly neutralizing antibody response against conserved elements of the HIV envelope. The structure of trimeric envelope spikes on intact HIV-1 virions (the target of neutralizing antibodies) was determined at low resolution using cryo-electron tomography. Fitting high-resolution crystal structures of monomeric gp120 complexed with different neutralizing ligands into the cryo-electron density maps provides useful models for the native virion trimer and for mechanisms of neutralization. SummarySo far, all attempts to elicit broadly neutralizing antibodies against HIV by immunization have failed. Recent structural information on the virion-associated HIV envelope spike and of the precise interaction of broadly neutralizing mAbs with their epitopes clarifies the steric and geometric constraints faced by antibodies targeting conserved HIV epitopes. Implications for vaccine design are discussed.

[1]  J. Sodroski,et al.  Identification and characterization of monoclonal antibodies specific for polymorphic antigenic determinants within the V2 region of the human immunodeficiency virus type 1 envelope glycoprotein , 1995, Journal of virology.

[2]  Mark Connors,et al.  Broad HIV-1 neutralization mediated by CD4-binding site antibodies , 2007, Nature Medicine.

[3]  N. Sullivan,et al.  Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120 , 1993, Journal of virology.

[4]  J. Shiver,et al.  An oligosaccharide-based HIV-1 2G12 mimotope vaccine induces carbohydrate-specific antibodies that fail to neutralize HIV-1 virions , 2008, Proceedings of the National Academy of Sciences.

[5]  H. Ellens,et al.  Binding of soluble CD4 proteins to human immunodeficiency virus type 1 and infected cells induces release of envelope glycoprotein gp120. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[6]  L. Morris,et al.  The C3-V4 Region Is a Major Target of Autologous Neutralizing Antibodies in Human Immunodeficiency Virus Type 1 Subtype C Infection , 2007, Journal of Virology.

[7]  Douglas D. Richman,et al.  Dissecting the Neutralizing Antibody Specificities of Broadly Neutralizing Sera from Human Immunodeficiency Virus Type 1-Infected Donors , 2007, Journal of Virology.

[8]  David Yang,et al.  The N-Terminal V3 Loop Glycan Modulates the Interaction of Clade A and B Human Immunodeficiency Virus Type 1 Envelopes with CD4 and Chemokine Receptors , 2000, Journal of Virology.

[9]  A. Pinter Roles of HIV-1 Env variable regions in viral neutralization and vaccine development. , 2007, Current HIV research.

[10]  Peter D. Kwong,et al.  Structure and Mechanistic Analysis of the Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5 in Complex with Its gp41 Epitope , 2004, Journal of Virology.

[11]  D R Burton,et al.  Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. off , 1997, Journal of virology.

[12]  Yang Liu,et al.  Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[13]  H. Katinger,et al.  The carbohydrate epitope of the neutralizing anti-HIV-1 antibody 2G12. , 2003, Advances in experimental medicine and biology.

[14]  Gira Bhabha,et al.  Antibody Recognition of a Highly Conserved Influenza Virus Epitope , 2009, Science.

[15]  Wei Zhang,et al.  Isolation and characterization of phage-displayed single chain antibodies recognizing nonreducing terminal mannose residues. 2. Expression, purification, and characterization of recombinant single chain antibodies. , 2007, Biochemistry.

[16]  L. Stamatatos,et al.  V2 Loop Glycosylation of the Human Immunodeficiency Virus Type 1 SF162 Envelope Facilitates Interaction of This Protein with CD4 and CCR5 Receptors and Protects the Virus from Neutralization by Anti-V3 Loop and Anti-CD4 Binding Site Antibodies , 2000, Journal of Virology.

[17]  John R. Mascola,et al.  Analysis of Neutralization Specificities in Polyclonal Sera Derived from Human Immunodeficiency Virus Type 1-Infected Individuals , 2008, Journal of Virology.

[18]  D. Montefiori,et al.  High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. , 2009, Virology.

[19]  H. Katinger,et al.  The Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2G12 Recognizes a Cluster of α1→2 Mannose Residues on the Outer Face of gp120 , 2002, Journal of Virology.

[20]  K. Tomer,et al.  Mass spectrometric characterization of the glycosylation pattern of HIV-gp120 expressed in CHO cells. , 2000, Biochemistry.

[21]  T. Mizuochi,et al.  Carbohydrate structures of the human-immunodeficiency-virus (HIV) recombinant envelope glycoprotein gp120 produced in Chinese-hamster ovary cells. , 1988, The Biochemical journal.

[22]  J. Sodroski,et al.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody , 1998, Nature.

[23]  Stephen D Fuller,et al.  Cryo-Electron Tomographic Structure of an Immunodeficiency Virus Envelope Complex In Situ , 2006, PLoS pathogens.

[24]  J. Sodroski,et al.  Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding , 1990, Journal of virology.

[25]  J. Moore,et al.  Macrophage-tropic and T-cell line-adapted chimeric strains of human immunodeficiency virus type 1 differ in their susceptibilities to neutralization by soluble CD4 at different temperatures , 1994, Journal of virology.

[26]  J. Sodroski,et al.  Effects of changes in gp120-CD4 binding affinity on human immunodeficiency virus type 1 envelope glycoprotein function and soluble CD4 sensitivity , 1991, Journal of virology.

[27]  J. Hoxie,et al.  Envelope Glycoprotein Incorporation, Not Shedding of Surface Envelope Glycoprotein (gp120/SU), Is the Primary Determinant of SU Content of Purified Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus , 2002, Journal of Virology.

[28]  Sriram Subramaniam,et al.  Electron Tomography of the Contact between T Cells and SIV/HIV-1: Implications for Viral Entry , 2007, PLoS pathogens.

[29]  L. Stamatatos,et al.  N-Linked Glycosylation of the V3 Loop and the Immunologically Silent Face of gp120 Protects Human Immunodeficiency Virus Type 1 SF162 from Neutralization by Anti-gp120 and Anti-gp41 Antibodies , 2004, Journal of Virology.

[30]  W. Weis,et al.  Structural basis of lectin-carbohydrate recognition. , 1996, Annual review of biochemistry.

[31]  Christoph Grundner,et al.  Access of Antibody Molecules to the Conserved Coreceptor Binding Site on Glycoprotein gp120 Is Sterically Restricted on Primary Human Immunodeficiency Virus Type 1 , 2003, Journal of Virology.

[32]  Xuesong Yu,et al.  Factors Associated with the Development of Cross-Reactive Neutralizing Antibodies during Human Immunodeficiency Virus Type 1 Infection , 2008, Journal of Virology.

[33]  J. Hoxie,et al.  Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralization. , 2008, Virology.

[34]  W. Weis Cell-surface carbohydrate recognition by animal and viral lectins. , 1997, Current opinion in structural biology.

[35]  Kenneth A. Taylor,et al.  Cryoelectron Tomography of HIV-1 Envelope Spikes: Further Evidence for Tripod-Like Legs , 2008, PLoS pathogens.

[36]  Renate Kunert,et al.  Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies , 2004, Journal of Virology.

[37]  Sara Sandin,et al.  Structure and flexibility of individual immunoglobulin G molecules in solution. , 2004, Structure.

[38]  K. Roux,et al.  Flexibility of human IgG subclasses. , 1997, Journal of immunology.

[39]  J. Binley,et al.  Nature of Nonfunctional Envelope Proteins on the Surface of Human Immunodeficiency Virus Type 1 , 2006, Journal of Virology.

[40]  Christoph Grundner,et al.  Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. , 2003, Virology.

[41]  A. West,et al.  Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10 , 2009, Proceedings of the National Academy of Sciences.

[42]  John P. Moore,et al.  Structure of the HIV-1 gp41 membrane-proximal ectodomain region in a putative prefusion conformation. , 2009, Biochemistry.

[43]  R. Doms,et al.  A Yeast Glycoprotein Shows High-Affinity Binding to the Broadly Neutralizing Human Immunodeficiency Virus Antibody 2G12 and Inhibits gp120 Interactions with 2G12 and DC-SIGN , 2009, Journal of Virology.

[44]  A. Trkola,et al.  Antibody responses in primary HIV-1 infection , 2008, Current opinion in HIV and AIDS.

[45]  J. Sodroski,et al.  Stoichiometry of Envelope Glycoprotein Trimers in the Entry of Human Immunodeficiency Virus Type 1 , 2005, Journal of Virology.

[46]  J. Hoxie,et al.  Human Immunodeficiency Virus Type 2 (HIV-2)/HIV-1 Envelope Chimeras Detect High Titers of Broadly Reactive HIV-1 V3-Specific Antibodies in Human Plasma , 2008, Journal of Virology.

[47]  James Paulson,et al.  Phage-display selection of a human single-chain fv antibody highly specific for melanoma and breast cancer cells using a chemoenzymatically synthesized G(M3)-carbohydrate antigen. , 2002, Journal of the American Chemical Society.

[48]  Q. Sattentau,et al.  Dissociation of gp120 from HIV-1 virions induced by soluble CD4. , 1990, Science.

[49]  G. Sapiro,et al.  Molecular architecture of native HIV-1 gp120 trimers , 2008, Nature.

[50]  E. Go,et al.  Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes' accessibility. , 2008, Journal of proteome research.

[51]  J. Skehel,et al.  Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. , 2000, Annual review of biochemistry.

[52]  H. Katinger,et al.  Exposure of the membrane-proximal external region of HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion. , 2007, Biochemistry.

[53]  D. Burton Antibodies, viruses and vaccines , 2002, Nature Reviews Immunology.

[54]  D. Burton,et al.  A Glycoconjugate Antigen Based on the Recognition Motif of a Broadly Neutralizing Human Immunodeficiency Virus Antibody, 2G12, Is Immunogenic but Elicits Antibodies Unable To Bind to the Self Glycans of gp120 , 2008, Journal of Virology.

[55]  D. Ho,et al.  Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120 , 1992, Journal of virology.

[56]  David F. Smith,et al.  An Engineered Saccharomyces cerevisiae Strain Binds the Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody 2G12 and Elicits Mannose-Specific gp120-Binding Antibodies , 2008, Journal of Virology.

[57]  J. Kappes,et al.  Emergence of Resistant Human Immunodeficiency Virus Type 1 in Patients Receiving Fusion Inhibitor (T-20) Monotherapy , 2002, Antimicrobial Agents and Chemotherapy.

[58]  Lynn Morris,et al.  Profiling the Specificity of Neutralizing Antibodies in a Large Panel of Plasmas from Patients Chronically Infected with Human Immunodeficiency Virus Type 1 Subtypes B and C , 2008, Journal of Virology.

[59]  Tongqing Zhou,et al.  Structural definition of a conserved neutralization epitope on HIV-1 gp120 , 2007, Nature.

[60]  Yifan Cheng,et al.  A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies , 2008, Proceedings of the National Academy of Sciences.

[61]  F. Bibollet-Ruche,et al.  Role of V1V2 and Other Human Immunodeficiency Virus Type 1 Envelope Domains in Resistance to Autologous Neutralization during Clade C Infection , 2007, Journal of Virology.

[62]  Q. Sattentau,et al.  Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4 , 1991, Journal of virology.

[63]  Uwe Karsten,et al.  Multivalent scFv display of phagemid repertoires for the selection of carbohydrate-specific antibodies and its application to the Thomsen-Friedenreich antigen. , 2004, Journal of molecular biology.

[64]  Boguslaw Stec,et al.  Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses , 2009, Nature Structural &Molecular Biology.

[65]  P. Rios,et al.  Freezing immunoglobulins to see them move. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[66]  R. Desrosiers,et al.  Glycosylation of gp41 of Simian Immunodeficiency Virus Shields Epitopes That Can Be Targets for Neutralizing Antibodies , 2008, Journal of Virology.

[67]  H. Katinger,et al.  A peptide inhibitor of HIV‐1 neutralizing antibody 2G12 is not a structural mimic of the natural carbohydrate epitope on gp120 , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[68]  S. Ohlson,et al.  Transiently binding antibody fragments against Lewis x and sialyl-Lewis x. , 2006, Journal of immunological methods.

[69]  Chi-Huey Wong,et al.  Targeting the carbohydrates on HIV-1: Interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN , 2008, Proceedings of the National Academy of Sciences.

[70]  B. Berkhout,et al.  The carbohydrate at asparagine 386 on HIV-1 gp120 is not essential for protein folding and function but is involved in immune evasion , 2008, Retrovirology.

[71]  Barbra A. Richardson,et al.  Removal of a Single N-Linked Glycan in Human Immunodeficiency Virus Type 1 gp120 Results in an Enhanced Ability To Induce Neutralizing Antibody Responses , 2007, Journal of Virology.

[72]  Robyn L Stanfield,et al.  Contrasting IgG structures reveal extreme asymmetry and flexibility. , 2002, Journal of molecular biology.

[73]  D. Richman,et al.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[74]  Peter D. Kwong,et al.  Antigenic conservation and immunogenicity of the HIV coreceptor binding site , 2005, The Journal of experimental medicine.

[75]  V. Brusic,et al.  HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. , 2008, Immunity.

[76]  J. Sodroski,et al.  Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1 , 1994, Journal of virology.

[77]  Renate Kunert,et al.  Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. , 2005, Immunity.

[78]  D. Burton,et al.  Inhibition of mammalian glycan biosynthesis produces non-self antigens for a broadly neutralising, HIV-1 specific antibody. , 2007, Journal of molecular biology.

[79]  P. S. Kim,et al.  HIV Entry and Its Inhibition , 1998, Cell.

[80]  J. Sodroski,et al.  Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody , 1993, Journal of virology.

[81]  D. Burton,et al.  Natural Resistance of Human Immunodeficiency Virus Type 1 to the CD4bs Antibody b12 Conferred by a Glycan and an Arginine Residue Close to the CD4 Binding Loop , 2008, Journal of Virology.

[82]  J. Lifson,et al.  Distribution and three-dimensional structure of AIDS virus envelope spikes , 2006, Nature.

[83]  J. McKeating,et al.  Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain , 1995, Journal of virology.

[84]  J. Mascola,et al.  Frequency and Phenotype of Human Immunodeficiency Virus Envelope-Specific B Cells from Patients with Broadly Cross-Neutralizing Antibodies , 2008, Journal of Virology.

[85]  Ping Zhu,et al.  Antibody Domain Exchange Is an Immunological Solution to Carbohydrate Cluster Recognition , 2003, Science.

[86]  Robyn L Stanfield,et al.  Antibody vs. HIV in a clash of evolutionary titans. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[87]  Richard T. Wyatt,et al.  Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals , 2009, Nature.

[88]  Reed J. Harris,et al.  Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. , 1990, The Journal of biological chemistry.

[89]  Pojen P. Chen,et al.  The Role of Antibody Polyspecificity and Lipid Reactivity in Binding of Broadly Neutralizing Anti-HIV-1 Envelope Human Monoclonal Antibodies 2F5 and 4E10 to Glycoprotein 41 Membrane Proximal Envelope Epitopes1 , 2007, The Journal of Immunology.

[90]  Peter D. Kwong,et al.  The antigenic structure of the HIV gp120 envelope glycoprotein , 1998, Nature.